- $24.59bn
- $21.44bn
- $8.26m
U.S. STOCKS ON THE MOVE-Royal Caribbean Cruises, AMC Entertainment, Roivant
Roivant rises as arthritis drug shows early promise
Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain
Brief: New England Journal Of Medicine Publishes Positive Phase 3 Valor Trial Results Of Brepocitinib In Dermatomyositis
Street View: Wall Street views Moderna's legal settlement as clearing a major overhang
Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute (updated)
Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute
Brief: Roivant Announces Genevant Sciences’ And Arbutus Biopharma’S $2.25 Billion Global Settlement With Moderna
Brief: Genevant Sciences And Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
Brief: Priovant Announces FDA Acceptance And Priority Review Of New Drug Application For Brepocitinib In Dermatomyositis
U.S. STOCKS ON THE MOVE-SpyGlass, Agomab, Piper Sandler, Molina
U.S. STOCKS ON THE MOVE-Microchip, Under Armour, Avery Dennison
U.S. STOCKS ON THE MOVE-Biogen, Bloom Energy, Ubiquiti
Brief: Priovant Announces Positive Phase 2 Results For Brepocitinib In Cutaneous Sarcoidosis (Cs)
Roivant shares rise as experimental drug shows benefit in rare skin disease
Roivant swings to Q3 loss as revenue drops
Arbutus Biopharma slips after Europe revokes key patent
Media: Proxima raises $80 million for AI drug discovery from DCVA, Nvidia - Bloomberg News
Brief: Roivant Highlights Continued Pipeline Progress And Outlook For Company’S Next Phase Of Growth At 2025 Investor Day